bioecon Member area
Technology · Agri-food systems / Food & alt-protein

Cellular Mitophagy Activation via Pure Ellagitannin Metabolite (Urolithin A)

Production and clinical application of pharmaceutical-grade, proprietary synthetic Urolithin A (Mitopure), a bioavailable postbiotic metabolite of pomegranate ellagitannins that crosses cell membranes and triggers PINK1/Parkin-mediated selective degradation of dysfunctional, depolarized mitochondria (mitophagy), clinically shown to enhance muscle endurance and cellular energy production in aging tissues.

1 · What it gives

Cellular mitophagy activation via the pure ellagitannin gut metabolite Urolithin A (UA; 3,8-dihydroxy-6H-benzo[c]chromen-6-one) represents a landmark therapeutic breakthrough in the science of cellular longevity and healthy aging. As human tissues age, cellular powerhouse mitochondria suffer cumulative oxidative damage, accumulating structural mutations and bioenergetic defects that drive sarcopenia, chronic low-grade inflammation (‘inflammaging’), and metabolic decline. While young cells eliminate damaged mitochondria via selective macroautophagy (mitophagy), aging tissues experience a progressive failure of this clearing mechanism. While dietary ellagitannins (found in pomegranates, walnuts, and berries) can theoretically be converted into Urolithin A by gut microbiota, clinical research reveals that only 30–40% of the human population harbors the specific microbiome species (e.g., Gordonibacter urolithinfaciens) required for this bioconversion, with variable and negligible yields.

Industrial chemical synthesis and precision biocatalytic routes now deliver pharmaceutical-grade, pure crystalline Urolithin A (>99% purity) as a standardized, bioavailable active compound. Orally administered Urolithin A directly activates the foundational PINK1/Parkin-dependent mitophagy cascade in skeletal muscle, cardiac tissue, and neurons. Clinical human randomized double-blind placebo-controlled trials confirm that a daily dosage of 500–1,000 mg of pure Urolithin A significantly enhances mitochondrial biogenesis, improves skeletal muscle endurance by over 12% in older adults, elevates aerobic capacity (VO2 max), and suppresses systemic inflammatory biomarkers (CRP, IL-6) without adverse side effects. The compound is actively commercialized as an elite longevity nutraceutical and is progressing through clinical trials for Duchenne muscular dystrophy and immune senescence.

The key directions of this technology are:

  1. Scalable Stereoselective Chemical & Biocatalytic Synthesis: Direct, high-yield organic synthesis or engineered microbial consortium biotransformation converting ellagic acid into pure, single-isomer Urolithin A at multiton scale.
  2. PINK1/Parkin Signaling & Mitochondrial Dynamics: Elucidating the exact molecular pharmacology whereby Urolithin A promotes mitochondrial membrane depolarization and selective LC3-II autophagosome recruitment.
  3. Bioavailability & Nanocrystal Formulation: Overcoming the poor aqueous solubility of Urolithin A via high-pressure wet bead milling to produce sub-200 nm nanocrystals with 3-fold higher oral absorption.
  4. Clinical Longevity & Muscular Dystrophy Applications: Phase 2/3 clinical translation for treating age-related sarcopenia, muscular dystrophies, and enhancing immune fitness in oncology patients.

Sectoral value chain#

[Ellagic Acid / Chemical Precursors] ──> [Regioselective Condensation / Cyclization] ──> [Continuous Decolorization & Crystallization]
                                                                                        │
                                                                            (Solvent Wash & Vacuum Drying)
                                                                                        │
                                                                                        ▼
[Longevity Supplements / Medical Food] <── [Nanocrystal Wet Milling & Formulation] <────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Raw Material Synthesis / SourcingHigh-purity chemical synthesis from 2-bromo-5-methoxybenzoic acid and resorcinol, or green extraction of ellagic acid from pomegranate rinds.In: Raw organic precursors, food-grade pomegranate extract.
Out: Standardized reaction precursor intermediates (>98% assay).
Ullmann-Type Coupling & CyclizationCopper-catalyzed Ullmann condensation followed by lactonization to form the core benzo[c]chromen-6-one tricyclic scaffold.In: Precursors, copper catalyst, alkaline aqueous phase.
Out: Crude Urolithin A intermediate solution.
Demethylation & Acidic CleavageDeprotection using Lewis acids (such as BBr3 or aqueous HBr) to liberate the pure 3,8-dihydroxy phenolic groups.In: Crude lactone intermediate, deprotecting reagent, water.
Out: Crude precipitate of Urolithin A.
Recrystallization & PurificationDissolving in food-grade glacial acetic acid or ethanol/water blends, followed by activated carbon decolorization and controlled cooling crystallization.In: Crude Urolithin A, food-grade solvent, activated carbon.
Out: High-purity crystalline Urolithin A cake (>99.0% purity).
Nanocrystal Milling & MicronizationWet pearl milling with polymeric stabilizers (PVP, sodium docusate) to achieve a narrow sub-micron particle distribution (D50 < 200 nm).In: Crystalline Urolithin A, food-grade surfactants, water.
Out: Aqueous nanocrystal suspension with 300% enhanced bioavailability.
Encapsulation & PackagingSpray-drying nanocrystals into free-flowing powder followed by hard-gel encapsulation or sachet filling under nitrogen purge.In: Urolithin A powder, pharmaceutical excipients, vegetarian capsules.
Out: Finished, shelf-stable consumer longevity nutraceutical.

Cross-cutting technologies of the sector:

  • High-Performance Liquid Chromatography (HPLC-DAD-MS): Validated analytical methodology separating Urolithin A from structural positional isomers (Urolithin B, Iso-urolithin A).
  • Respirometry (Seahorse XF Cell Mito Stress Test): Quantifying real-time cellular oxygen consumption rates (OCR) and spare respiratory capacity in treated myoblasts.
  • Automated Confocal High-Content Imaging: Fluorescence tracking of mKeima and mt-Rosella biosensors measuring real-time autophagic flux to acidic lysosomes.

2 · What it replaces 6 · matched by industry

D2E–Enzymatic degumming (phospholipases) and enzymatic interesterification (immobilized lipases) of edible oils instead of acid–caustic chemical degumming and sodium-methoxide chemical interesterification
Replaces: Phosphoric/citric acid plus caustic soda degumming and neutralization (soapstock, wastewater, oil losses); chemical interesterification with …
FOOD
D1E2Natural antioxidants — tocopherols, rosemary extract, ascorbyl palmitate — instead of BHA and BHT
Replaces: Synthetic phenolic antioxidants BHA (E320) and BHT (E321) in fats, oils, snacks, cereals, meat and fish products; part of synthetic …
FOOD
D3E–Fermentation-produced vitamins (B2, B12, C routes) instead of multi-step chemical synthesis
Replaces: Chemical vitamin synthesis — Reichstein process for vitamin C (six chemical steps + one fermentation), chemical B2 routes (abandoned), …
FOOD
D1E–Baking enzymes (fungal amylase, maltogenic amylase, xylanase, glucose oxidase, lipase) plus ascorbic acid instead of potassium bromate and azodicarbonamide as flour treatment agents
Replaces: Potassium bromate (KBrO₃) and azodicarbonamide (ADA) used as oxidizing flour improvers/dough conditioners; part of chemical emulsifier use …
FOOD
D3E–Citric acid by Aspergillus niger fermentation instead of extraction from citrus fruit
Replaces: Citric acid extracted from lemons, limes and other citrus (calcium citrate route, Italy and California before 1930)
FOOD
D3E–Enzymatic high-fructose syrup from starch instead of sucrose and acid hydrolysis
Replaces: Cane and beet sucrose in beverages and processed foods; acid hydrolysis of starch for glucose syrup
FOOD

3 · How to implement 4 steps

  1. 1
    Scalable cGMP chemical synthesis of pure Urolithin A
    Synthesizing pharmaceutical-purity Urolithin A devoid of heavy metals, achieving single polymorph micro-crystals.
  2. 2
    In-vitro PINK1/Parkin mitophagy induction assays
    Validating mitochondrial clearance and autophagosome formation in primary myoblasts using fluorescence microscopy.
  3. 3
    Clinical pharmacokinetic and muscle endurance trials
    Demonstrating oral bioavailability, sustained plasma levels, and statistically significant increases in muscle strength.
  4. 4
    High-bioavailability lipid formulation for oral capsules
    Formulating micro-ground crystalline powder into softgel lipid capsules that maximize gastrointestinal absorption.

4 · Who delivers

Matched suppliers (matched automatically)

Shenzhen Hygieia Biotech 希吉亚ChinaProduceractive
IntegricultureJapanEquipmentactive
AbinopharmUnited StatesProduceractive
AmazentisSwitzerlandProduceractive
Rev GenomicsUnited StatesProduceractive
Altos LabsUnited StatesResearch / RTOactive
FermenstationJapanProduceractive
FermelantaJapanProduceractive
Esco AsterSingaporeServices / consultingactive
AlgalifIcelandProduceractive
CalystaUnited StatesProduceractive
Aleph FarmsIsraelProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Amazentis (Timeline Nutrition)🇨🇭 SwitzerlandMitopure® / Urolithin A PlatformPioneer and global IP holder of clinically validated Urolithin A for cellular longevity and muscle vitalitycommercial
ChromaDex🇺🇸 USACellular Health IngredientsLeading pioneer in NAD+ precursors and longevity chemistry, exploring synergistic cellular health activescommercial
Lonza🇨🇭 SwitzerlandCapsules & Health Ingredients CDMOWorld-leading CDMO manufacturing advanced encapsulated lipid formulations of functional longevity activescommercial
Gnosis by Lesaffre🇫🇷 FranceFermentation & Bioactive ActivesBiotechnology leader producing specialized bioactives and nutritional cofactors for mitochondrial healthcommercial
Elysium Health🇺🇸 USACellular Longevity FormulationsDirect-to-consumer biotech brand formulating clinically tested cellular repair and healthspan supplementscommercial
Nektium🇪🇸 SpainBotanical Bioactive ActivesSpecialist manufacturer of standardized botanical extracts exploring natural polyphenol bioconversioncommercial
Fenchem Biotek🇨🇳 ChinaBulk Urolithin A APIMajor high-capacity supplier of cGMP synthetic Urolithin A powders for global nutraceutical brandscommercial

5 · Rules & route to market

Route into Russia / EAEU: FOOD · Rospotrebnadzor / EAEU
declaration of conformity, or SGR within 30 calendar days for new/specialized ingredients (plus tests)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

FDA GRAS Notices, Elite Longevity Clinics, and NIH Muscle Grants#

  • FDA GRAS No-Objection Letters: Formal GRAS notice approvals (GRN 791) confirming safety for inclusion in nutrition bars, protein shakes, and dietary supplements.
  • Booming Longevity Sector: Rapid adoption across preventative wellness clinics and athletic performance institutes across California and Florida.
  • NIH & Clinical Trials: Federal research grants funding clinical exploration of Urolithin A for cognitive preservation in Alzheimer’s disease and cardiometabolic health.

European Union

Swiss Cleantech Pioneer (Amazentis / Timeline), EPFL Innovation, and EFSA#

  • Swiss Innovation Epicenter: Amazentis (EPFL spin-off, Lausanne) leading global R&D and clinical trials with its proprietary Mitopure® Urolithin A platform.
  • Strategic Corporate Backing: Multi-million Swiss franc investments by Nestlé Health Science and L’Oréal venturing into cellular longevity skin-nutrition products.
  • EFSA Novel Food Clearance: European Food Safety Authority positive safety opinion authorizing high-purity synthetic Urolithin A across the European Union.

China

14th Five-Year Healthy Aging Strategy, Pomegranate Extraction, and TCM Modernization#

  • National Healthy China 2030 Mandates: Heavy focus on anti-sarcopenia and healthy aging interventions to support China’s rapidly aging demographic.
  • Pomegranate Agriculture in Xinjiang and Yunnan: Mega-scale extraction hubs utilizing regional pomegranate processing residues to source ellagitannins.
  • Domestic CDMO Chemical Synthesis: Leading pharmaceutical CDMOs in Zhejiang and Jiangsu establishing cGMP chemical synthesis lines for multi-ton Urolithin A exports.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Stereospecific Ullmann Coupling Parameters:
    • Reaction of 2-bromo-5-methoxybenzoic acid with resorcinol in aqueous alkaline medium catalyzed by copper sulfate (CuSO4).
    • Operated at 80–90°C under nitrogen atmosphere, achieving >85% isolated yield of the lactone intermediate.
    • Subsequent ether cleavage with 48% aqueous hydrobromic acid at reflux cleanly yields crude Urolithin A.
  2. Recrystallization and Residual Impurity Stripping:
    • Dissolution in food-grade glacial acetic acid at 110°C, followed by treatment with 2 wt% medical-grade activated carbon.
    • Programmed cooling crystallization (1°C/min) down to 15°C, yielding needle-like yellow-white crystalline polymorphs.
    • Eliminates copper catalyst residuals to strictly <1 ppm and residual solvents to <50 ppm, well below ICH guidelines.
  3. Nanocrystal Wet Bead Milling Kinetics:
    • Agitator bead mill utilizing 0.1 mm yttria-stabilized zirconia (YSZ) grinding beads at tip speeds >12 m/s.
    • PVP K30 and sodium lauryl sulfate maintain electrostatic steric repulsion, preventing particle agglomeration.
    • Particle diameter D90 < 250 nm accelerates dissolution rate by 400% in simulated intestinal fluid (FaSSIF).

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22